Platelet-monocyte interaction and GPIIb/IIIa blockade

Lian Zhao; Philip Bath; Wolfgang Lösche; Stan Heptinstall

doi:10.1055/s-0037-1614197

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2004; 92(04): 888-890
DOI: 10.1055/s-0037-1614197

Letters to the Editor

Schattauer GmbH

Platelet-monocyte interaction and GPIIb/IIIa blockade

Lian Zhao

¹Institute for Clinical Research, and University of Nottingham, UK

²Institute of Neuroscience, University of Nottingham, UK

,

Philip Bath

¹Institute for Clinical Research, and University of Nottingham, UK

²Institute of Neuroscience, University of Nottingham, UK

,

Wolfgang Lösche

³Clinic of Anaesthesiology and Intensive Care Medicine, University Hospital Jena, Germany

,

Stan Heptinstall

¹Institute for Clinical Research, and University of Nottingham, UK

› Author Affiliations

Abstract

Full Text

References

References
1 Quinn MJ, Moliterno DJ. Platelet glycoprotein Ilb/IIIa inhibitors in acute coronary syndromes. Minerva Cardioangiol 2002; 50: 547-53.
2 Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein Ilb/IIIa inhibitors: recognition of a two-edged sword?. Circulation 2002; 106: 379-85.
3 Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1886-9.
4 Dalby M, Montalescot G, Sollier CB. et al. Ep-tifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol 2004; 43: 162-8.
5 Scholz T, Zhao L, Temmler U. et al. The GPI-Ib/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Platelets 2002; 13: 401-6.
6 Zhao L, Bath PM, Fox S. et al. The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions. Curr Med Res Opin 2003; 19: 178-86.
7 Redlich H, Vickers J, Losche W. et al. Formation of platelet-leukocyte conjugates in whole blood. Platelets 1997; 08: 419-25.
8 Sanderson HM, Fox SC, Robbins RA. et al. Role of GPIIb-IIIa in platelet-monocyte and platelet-neutrophil conjugate formation in whole blood. Platelets 1998; 09: 245-50.
9 Li N, Hu H, Lindqvist M. et al. Platelet-Leukocyte Cross Talk in Whole Blood. Arterioscler Thromb Vasc Biol 2000; 20: 2702-8.
10 Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 2002; 71: 176-85.
11 Hu H, Varon D, Hjemdahl P. et al. Platelet-leukocyte aggregation under shear stress: differential involvement of selectins and inte-grins. Thromb Haemost 2003; 90: 679-87.
12 Neumann F-J, Zohlnhofer D, Fakhoury L. et al. Effect of glycoprotein Ilb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Cardiol 1999; 34: 1420-6.
13 Steiner S, Seidinger D, Huber K. et al. Effect of glycoprotein Ilb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression. Arterioscler Thromb Vasc Biol 2003; 23: 1697-702.
14 Yuan AS, Hand EL, Hichens M. et al. Determination of MK-852, a new fibrinogen receptor antagonist, in plasma and urine by radioimmunoassay. J Pharm Biomed Anal 1993; 11: 427-34.
15 Bednar RA, Gaul SL, Hamill TG. et al. Identification of low molecular weight GP Ilb/IIIa antagonists that bind preferentially to activated platelets. J Pharmacol Exp Ther 1998; 285: 1317-26.
16 Storey RF, Wilcox RG, Heptinstall S. Differential effects of glycoprotein Ilb/IIIa antagonists on platelet microaggregate and macroag-gregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. Circulation 1998; 98: 1616-21.
17 Greenberg HE, Wissel P, Barrett J. et al. Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers. J Clin Pharmacol 2000; 40: 496-507.
18 May AE, Neumann FJ, Gawaz M. et al. Reduction of monocyte-platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation. Eur Heart J 1997; 18: 1913-20.
19 Mickelson JK, Ali MN, Kleiman NS. et al. Chimeric 7E3 Fab (ReoPro) decreases detectable CDllb on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 1999; 33: 97-106.
20 Furman MI, Kereiakes DJ, Krueger LA. et al. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J 2001; 142: 790-8.
21 Kopp CW, Steiner S, Nasel C. et al. Abciximab Reduces Monocyte Tissue Factor in Carotid Angioplasty and Stenting. Stroke 2003; 34: 2560-7.
22 Fredrickson BJ, Turner NA, Kleiman NS. et al. Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. Circulation 2000; 101: 1122-9.